← Eichor
Condition: Recurrent Glioblastoma Idh Wildtype Synced from ClinicalTrials.gov · July 28, 2026

Recruiting studies: Recurrent Glioblastoma Idh Wildtype

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

[177Lu]Lu-DOTA-EB-RGD2 Therapy in Patients With Recurrent High-grade Glioma
EARLY_Phase 1 · 2 location(s) · Beijing Tiantan Hospital · NCT07655869ERAS-801 for the Treatment of Resectable and Progressive or Recurrent or Elderly Newly Diagnosed IDH Wildtype Grade IV G
Phase 1 · 2 location(s) · Jonsson Comprehensive Cancer Center · NCT07089641The RECSUR-study: Resection Versus Best Oncological Treatment for Recurrent Glioblastoma (ENCRAM 2302)
Phase N/A · 8 location(s) · Jasper Gerritsen · NCT06283927Testing the Addition of an Anti-Cancer Drug, Triapine, to the Usual Radiation Therapy for Recurrent Glioblastoma or Astr
Phase 1 · 43 location(s) · National Cancer Institute (NCI) · NCT06860594Efineptakin Alfa and Pembrolizumab for the Treatment of Recurrent Glioblastoma
Phase 2 · 1 location(s) · Mayo Clinic · NCT05465954Triapine in Combination With Temozolomide for the Treatment of Patients With Recurrent Glioblastoma
Phase 1 · 1 location(s) · Northwestern University · NCT06410248GI-102 Alone or With Pembrolizumab Before Surgery for Treatment of Recurrent or Progressive IDH Wildtype Glioblastoma an
Phase 2 · 1 location(s) · Mayo Clinic · NCT07301268TTFields Plus FET-PET-Guided Stereotactic Radiosurgery Versus TTFields Alone for Recurrent Glioblastoma (Tarrget 2.0)
NA · 1 location(s) · Prof. Franciszek Lukaszczyk Memorial Oncology Center · NCT07668869A Clinical Trial of P134 Cells in Recurrent Glioblastoma
Phase 1/Phase 2 · 1 location(s) · Tasly Pharmaceutical Group Co., Ltd · NCT07318818Novel Indenoisoquinolone CMYC/TOPOISOMERASE 1 Inhibitor (LMP744) in Recurrent Glioblastoma
Phase 1/Phase 2 · 1 location(s) · National Institute of Neurological Disorders and Stroke (NIN · NCT07416188Locoregional Administration of Genetically Engineered Cells (EGFR/IL13Rα2 Pool-CAR T Cells) for the Treatment of Recurre
Phase 1 · 1 location(s) · City of Hope Medical Center · NCT07544992A Study of Debio 0123 in Combination With Temozolomide in Adult Participants With Recurrent or Progressive Glioblastoma
Phase 1/Phase 2 · 16 location(s) · Debiopharm International SA · NCT05765812A Surgical Window of Opportunity Clinical Trial of Troriluzole in Recurrent IDH Wild-Type Glioblastoma
EARLY_Phase 1 · 3 location(s) · Ugonma Chukwueke · NCT06552260Allogenic Adipose-Derived Mesenchymal Stem Cells for the Treatment of Recurrent Glioblastoma or Recurrent Astrocytoma in
Phase 1 · 1 location(s) · Mayo Clinic · NCT05789394The RECMAP-study: Resection With or Without Intraoperative Mapping for Recurrent Glioblastoma
Phase N/A · 8 location(s) · Erasmus Medical Center · NCT06273176Dosimetry, Safety, and Efficacy Study of [177Lu]Lu-XT771 in Patients With Recurrent Glioblastoma
EARLY_Phase 1 · 2 location(s) · Beijing Tiantan Hospital · NCT07648823D2C7-IT + 2141-V11 Combination Post-resection in rGBM
Phase 1 · 1 location(s) · Darell Bigner · NCT06455605A Trial to Evaluate Multiple Regimens in Newly Diagnosed and Recurrent Glioblastoma
Phase 2/Phase 3 · 63 location(s) · Global Coalition for Adaptive Research · NCT03970447Study of Metabolic, Transcriptomic and Proteomic Characteristics in Relapsed Glioblastoma
Phase N/A · 1 location(s) · University Hospital, Bordeaux · NCT06430424Testing the Addition of an Anti-cancer Drug, Selinexor, to the Usual Chemotherapy Treatment (Temozolomide) for Brain Tum
Phase 1/Phase 2 · 36 location(s) · National Cancer Institute (NCI) · NCT05432804
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.